California is currently home to 5931 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adaptive Intervention to Facilitate PrEP Uptake/Adherence Among Transgender Women
Recruiting
"PrEP N' Shine" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Transgender women (TGW).
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/02/2022
Locations: UCLA Center for LGBTQ+ Advocacy, Research & Health, Los Angeles, California
Conditions: Prevention
Integrating Support Persons Into Recovery
Recruiting
INtegrated Support Persons Into Recovery (INSPIRE) is a 4-year research project that tests whether integrating a patient's support person into a patient's treatment with Buprenorphine/Naloxone can improve outcomes. The study will examine whether a counseling program called CRAFT for a support person, such as a family member, spouse or friend, can improve patient outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2022
Locations: Lifelong Medical Care, Berkeley, California
Conditions: Opioid Addiction
VascTrac Peripheral Arterial Disease (PAD) Study
Recruiting
VascTrac is a mobile medical application that tracks users' physical activity levels in order to predict endovascular failure of patients with Peripheral Artery Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2022
Locations: VA Palo Alto Health Care System, Palo Alto, California
Conditions: Peripheral Artery Disease, Intermittent Claudication
HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)
Recruiting
The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydrocephalus. In addition to philanthropic funding, the HCRN has also received an NIH NINDS Challenge Grant to support the network infrastructure which allows for the conduct of this and other network studies. The HCRN consists of multiple Clinical Centers and the Data Coordinating Center (DCC). The HCRN... Read More
Gender:
All
Ages:
18 years and below
Trial Updated:
11/02/2022
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Pediatric Hydrocephalus
Pediatric Cervical Spine Clearance: A Multicenter Prospective Observational Study
Recruiting
A prospective multicenter observational study, led by Dr. Katie Russell of Intermountain Primary Children's Hospital, that will examine the sensitivity, specificity, negative, and positive predictive values of CT scan and plain films in diagnosing cervical spine injury that requires treatment. This study is funded by the Primary Children's Hospital foundation.
Gender:
All
Ages:
Between 0 years and 17 years
Trial Updated:
11/01/2022
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Cervical Spine Fracture
SoCal Savvy: Testing Savvy Caregiver in a Racially and Ethnically Diverse Sample in Southern California
Recruiting
The investigators will conduct a hybrid efficacy-effectiveness trial intended to address these gaps by testing the efficacy-effectiveness of two multi-family group interventions, and on 250 English-speaking adults: Savvy Caregiver Express™ (3-session, newly piloted in Los Angeles County for feasibility) and Savvy Caregiver Program (original 6-session evidenced-based intervention), across post-intervention, 3- and 6-months.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2022
Locations: University of Southern California, Los Angeles, California
Conditions: Caregiver Burnout, Psychological Distress
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Recruiting
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2022
Locations: GSK Investigational Site, Beverly Hills, California
Conditions: Multiple Myeloma
Optimizing IV Gentamicin in JEB
Recruiting
Herlitz junctional epidermolysis bullosa (H-JEB), an incurable and fatal inherited skin disease, is caused by loss-of-function mutations in LAMA3, LAMB3 and LAMC2. These mutations result in diminished laminin 332 and epidermal-dermal adherence. 85% of JEB patients have nonsense mutations in LAMA3, LAMB3, or LAMC2, suggesting that H-JEB is a prime therapeutic target for nonsense suppression therapy. The investigators recently demonstrated in three patients that topical gentamicin created new and... Read More
Gender:
All
Ages:
30 days and above
Trial Updated:
11/01/2022
Locations: University of Southern California, Los Angeles, California
Conditions: Junctional Epidermolysis Bullosa
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recruiting
Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable, devastating, inherited skin disease caused by mutations in the COL7A1 gene that encodes for type VII collagen (C7), the major component of anchoring fibrils (AFs), structures that mediate epidermal-dermal adherence. Thirty percent of RDEB patients have nonsense mutations. The investigators recently demonstrated in 5 such patients that intradermal and topical gentamicin induced "read-through" of their nonsense mutations and create... Read More
Gender:
All
Ages:
7 years and above
Trial Updated:
11/01/2022
Locations: University of Southern California, Los Angeles, California
Conditions: Recessive Dystrophic Epidermolysis Bullosa
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting
An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.
Gender:
All
Ages:
30 years and above
Trial Updated:
10/31/2022
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California
Conditions: Stroke, TIA, Ischemic Stroke, Ischemic
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Recruiting
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Gender:
All
Ages:
All
Trial Updated:
10/31/2022
Locations: Doheny Eye Center UCLA, Fountain Valley, California
Conditions: Glaucoma, Ocular Surface Disease
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
Recruiting
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: Balboa Research, La Jolla, California
Conditions: Hyperkalemia